Home›Stock Screener›Gujarat Themis Biosyn›Quarterly Results

Gujarat Themis Biosyn Quarterly Results

Latest Quarter Net Profit
₹11 Cr
QMar 2026
Quarterly Results

Gujarat Themis Biosyn quarterly results. In Mar 2026, Gujarat Themis Biosyn (GUJTHEM) reported revenue ₹45 Cr and net profit ₹11 Cr. For annual financials, live price and key ratios, visit Gujarat Themis Biosyn share price chart.

GUJTHEM Quarterly Results — Revenue, Profit & EPS Highlights

Gujarat Themis Biosyn latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check Gujarat Themis Biosyn market cap to track the company's total market size over time.

  • Revenue of ₹45 Cr in Mar 2026 (+2.3% vs Jun 2026)
  • Net Profit of ₹11 Cr in Mar 2026 (+0.0% vs Jun 2026)
  • EBITDA of ₹20 Cr in Mar 2026 (-4.8% vs Jun 2026)
  • Operating Margin of 44.0% in Mar 2026 (-3.0pp vs Jun 2026)
  • Earnings Per Share of ₹1.00 in Mar 2026 (-2.0% vs Jun 2026)

Gujarat Themis Biosyn Quarterly Results — Revenue, EBITDA, Net Profit & EPS

GUJTHEM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Jun 2025 QoQ YoY
Revenue (₹ Cr) 45 44 36 2.3% -
Net Profit (₹ Cr) 11 11 9 - -
EBITDA (₹ Cr) 20 21 14 - -
EPS (₹) 1.00 1.02 0.83 - -
Operating Margin (%) 44.0% 47.0% 39.0% - -

GUJTHEM Share Price Trend — 1-Year Movement Across Quarterly Results

Gujarat Themis Biosyn 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review GUJTHEM P/E ratio to evaluate earnings-based valuation against sector peers.

Profitability Ratios

Profit Margin 24.4%
EBITDA Margin 44.4%
Operating Margin 44.0%
ROE (Annual) 15.3%

Balance Sheet Highlights

Total Assets ₹503 Cr
Total Equity ₹288 Cr
Current Assets ₹89 Cr
Current Liabilities ₹137 Cr

Cash Flow Analysis

Operating Cash Flow ₹49 Cr
Investing Cash Flow ₹-172 Cr
Financing Cash Flow ₹115 Cr
Net Cash Flow ₹-9 Cr

Current Market Data

Current Price ₹373.60
Exchange NSE
Last Updated Oct 05, 2026

Revenue Trend (₹ Cr)

Jun 2025 36
Jun 2026 44
Mar 2026 45

Net Profit Trend (₹ Cr)

Jun 2025 9
Jun 2026 11
Mar 2026 11

Operating Margin Trend (%)

Jun 2025 39.0%
Jun 2026 47.0%
Mar 2026 44.0%

GUJTHEM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Gujarat Themis Biosyn latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹432,120.23 Cr 1779.7 15,018 2,710 -5.6% - 18.0% 157.5
Divis Laboratories
Mar 2026 		₹253,522.49 Cr 9196.0 2,986 751 -5.0% - 25.2% 324.8
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4772.0 4,111 364 +27.7% +42.2% 8.9% 414.6
Zydus Life Science
Mar 2026 		₹113,615.69 Cr 1139.0 7,569 1,341 -4.3% - 17.7% 90.0
Cipla
Mar 2026 		₹108,576.18 Cr 1335.5 6,612 543 -9.3% - 8.2% 194.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores